Level Four Advisory Services LLC Lowers Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Level Four Advisory Services LLC lowered its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 16.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,064 shares of the medical equipment provider’s stock after selling 206 shares during the quarter. Level Four Advisory Services LLC’s holdings in Intuitive Surgical were worth $359,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Intuitive Surgical by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock valued at $8,730,184,000 after acquiring an additional 196,316 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Intuitive Surgical by 2.0% during the 4th quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock worth $1,516,222,000 after purchasing an additional 88,977 shares during the period. Invesco Ltd. grew its holdings in shares of Intuitive Surgical by 6.6% during the 3rd quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock worth $1,096,231,000 after purchasing an additional 232,205 shares during the period. Northern Trust Corp grew its holdings in shares of Intuitive Surgical by 3.4% during the 3rd quarter. Northern Trust Corp now owns 3,514,421 shares of the medical equipment provider’s stock worth $1,027,230,000 after purchasing an additional 115,059 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Intuitive Surgical by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,094,141 shares of the medical equipment provider’s stock worth $706,479,000 after acquiring an additional 63,726 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The disclosure for this sale can be found here. Insiders sold 148,290 shares of company stock worth $57,207,154 in the last 90 days. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Stock Down 0.3 %

ISRG opened at $400.90 on Thursday. The firm has a market capitalization of $142.20 billion, a P/E ratio of 72.36, a price-to-earnings-growth ratio of 5.19 and a beta of 1.39. The stock’s 50 day moving average price is $386.00 and its two-hundred day moving average price is $360.92. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $408.43.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.00 EPS. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Mizuho upped their price target on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Piper Sandler upped their price target on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research report on Friday, April 19th. Citigroup upped their price target on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Raymond James upped their price target on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Finally, StockNews.com lowered Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.